Evidence map›Paper›PMID 37463576›Full record

ArticleCell metabolism2023

Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis.

Hyunsoo Rho, Alexander R Terry, Constantinos Chronis, Nissim Hay

Open access · bronzeAbstract read
In one paragraph

Article in Cell metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 261 papers.

0numbers the graph read from it
0cells of the map it votes in
261citing papers in PubMed
61.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

261 citing papers in PubMed, 300 citations in OpenAlex.

  1. Review
  2. Lactate Signal: Modulator of Cellular Energy Production and Anabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Article
  5. Precision pathophysiology in steatotic liver disease.Clinical and molecular hepatology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

201 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hyunsoo RhoDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.
Alexander R TerryDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.
Constantinos ChronisDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA.
Nissim HayDepartment of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA; Research and Development Section, Jesse Brown VA Medical Center, Chicago, IL 60612, USA. Electronic address: nhay@uic.edu.
University of Illinois Chicago · US

Funding

PI3K/PTEN/Akt signaling and the genesis of cancerR01CA090764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Nissim Hay · 2001 to 2026
$9.4M
The Role of Akt in Cell Survival and Cell GrowthR01AG016927 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 1998 to 2023
$9.0M
Hexokinase 2 and cancer therapyR01CA258299 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 2021 to 2025
$2.7M
Hexokinase 2 in liver cancerR01CA206167 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 2016 to 2020
$2.1M
Exploiting Metabolic Changes in HCC for Cancer TherapyF30CA225058 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI TERRY, ALEXANDER RICHARD · 2018 to 2022
$241k
The role of AMPK and CD36 in breast cancer tumorigenesis and metastasisI01BX005092 · VA · JESSE BROWN VA MEDICAL CENTER · PI HAY, NISSIM · 2021 to 2025
–
Hexokinase 2 and cancer therapyI01BX000733 · VA · JESSE BROWN VA MEDICAL CENTER · PI HAY, NISSIM · 2012 to 2020
–
BLRD VA I01 BX000733BLRD VA I01 BX005092BLRD VA IK6 BX004602NCI NIH HHS F30 CA225058NCI NIH HHS R01 CA090764NCI NIH HHS R01 CA206167NCI NIH HHS R01 CA258299NIA NIH HHS R01 AG016927
6 · The paper itself

Abstract

Lactate was implicated in the activation of hepatic stellate cells (HSCs). However, the mechanism by which lactate exerts its effect remains elusive. Using RNA-seq and CUT&Tag chromatin profiling, we found that induction of hexokinase 2 (HK2) expression in activated HSCs is required for induced gene expression by histone lactylation but not histone acetylation. Inhibiting histone lactylation by Hk2 deletion or pharmacological inhibition of lactate production diminishes HSC activation, whereas exogenous lactate but not acetate supplementation rescues the activation phenotype. Thus, lactate produced by activated HSCs determines the HSC fate via histone lactylation. We found that histone acetylation competes with histone lactylation, which could explain why class I HDAC (histone deacetylase) inhibitors impede HSC activation. Finally, HSC-specific or systemic deletion of HK2 inhibits HSC activation and liver fibrosis in vivo. Therefore, we provide evidence that HK2 may be an effective therapeutic target for liver fibrosis.

Indexed as

HexokinaseHistonesGene ExpressionHepatic Stellate CellsHumansLactatesLiver CirrhosisHexokinaseHistonesLactateshexokinase 2histone lactylationliver fibrosis

Identifiers

PMID37463576
PMCPMC11748916
OpenAlexW4384564258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.